147 related articles for article (PubMed ID: 9363322)
1. Tissue platinum after clinical treatment with cisplatin or carboplatin in tumor-bearing patients.
Minami T; Tohno Y; Tohno S; Utsumi M; Yamada M; Hashii K; Tateyama I; Kadota E; Okazaki Y
Biol Trace Elem Res; 1997; 58(1-2):77-83. PubMed ID: 9363322
[TBL] [Abstract][Full Text] [Related]
2. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
3. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration.
Esteban-Fernández D; Verdaguer JM; Ramírez-Camacho R; Palacios MA; Gómez-Gómez MM
J Anal Toxicol; 2008 Mar; 32(2):140-6. PubMed ID: 18334097
[TBL] [Abstract][Full Text] [Related]
4. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of carboplatin.
van der Vijgh WJ
Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899
[TBL] [Abstract][Full Text] [Related]
6. Platinum accumulation in the kidney and liver following chemotherapy with cisplatin in humans.
Uozumi J; Ueda T; Yasumasu T; Koikawa Y; Naito S; Kumazawa J; Sueishi K
Int Urol Nephrol; 1993; 25(3):215-20. PubMed ID: 8225820
[TBL] [Abstract][Full Text] [Related]
7. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
Hecquet B; Caty A; Fournier C; Lefebvre JL; Adenis L
Bull Cancer; 1987; 74(4):433-6. PubMed ID: 3311237
[TBL] [Abstract][Full Text] [Related]
8. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
[TBL] [Abstract][Full Text] [Related]
9. Platinum concentrations in uterus and serum after internal iliac arterial infusion of platinum compounds in rabbits.
Kigawa J; Minagawa Y; Itamochi H; Kanamori Y; Ishihara H; Terakawa N
Obstet Gynecol; 1995 Aug; 86(2):265-8. PubMed ID: 7617358
[TBL] [Abstract][Full Text] [Related]
10. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of platinum in the intervertebral discs and vertebrae of ovarian tumor-bearing patients treated with cisplatin.
Minami T; Hashii K; Tateyama I; Kadota E; Tohno Y; Tohno S; Utsumi M; Yamada MO; Ichii M; Namikawa K
Biol Trace Elem Res; 1994 Sep; 42(3):253-7. PubMed ID: 7826818
[TBL] [Abstract][Full Text] [Related]
12. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity.
Thomas JP; Lautermann J; Liedert B; Seiler F; Thomale J
Mol Pharmacol; 2006 Jul; 70(1):23-9. PubMed ID: 16569706
[TBL] [Abstract][Full Text] [Related]
13. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
14. Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.
Jandial DD; Messer K; Farshchi-Heydari S; Pu M; Howell SB
Gynecol Oncol; 2009 Dec; 115(3):362-6. PubMed ID: 19775736
[TBL] [Abstract][Full Text] [Related]
15. Pt-Mal-LHRH, a Newly Synthesized Compound Attenuating Breast Cancer Tumor Growth and Metastasis by Targeting Overexpression of the LHRH Receptor.
Calderon LE; Keeling JK; Rollins J; Black CA; Collins K; Arnold N; Vance DE; Ndinguri MW
Bioconjug Chem; 2017 Feb; 28(2):461-470. PubMed ID: 27997127
[TBL] [Abstract][Full Text] [Related]
16. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.
Parker RJ; Gill I; Tarone R; Vionnet JA; Grunberg S; Muggia FM; Reed E
Carcinogenesis; 1991 Jul; 12(7):1253-8. PubMed ID: 2070490
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
18. Distribution of platinum in human gynecologic tissues and lymph nodes after intravenous and intraarterial neoadjuvant chemotherapy.
Ishikawa H; Kikkawa F; Tamakoshi K; Matsuzawa K; Kawai M; Suganuma N; Tomoda Y
Anticancer Res; 1996; 16(6B):3849-53. PubMed ID: 9042269
[TBL] [Abstract][Full Text] [Related]
19. Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.
Thomas HD; Porter DJ; Bartelink I; Nobbs JR; Cole M; Elliott S; Newell DR; Calvert AH; Highley M; Boddy AV
Br J Clin Pharmacol; 2002 Jan; 53(1):83-91. PubMed ID: 11849199
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetic properties of platinium derivatives].
Boisdron-Celle M; Lebouil A; Allain P; Gamelin E
Bull Cancer; 2001 Aug; 88 Spec No():S14-9. PubMed ID: 11567909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]